ASH 2019 – Ixazomib with rituximab and dexamethasone effective in Waldenstrom’s macroglobulinemia


  • W. Todd Penberthy, Ph.D.
  • Univadis
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Combination treatment with ixazomib citrate, rituximab, and dexamethasone is feasible, shows promising efficacy, and manageable toxicity in patients with relapsed or progressive Waldenstrom’s macroglobulinemia.

Why this matters

  • Proteasome inhibitors like bortezomib have shown considerable efficacy in treating progressive Waldenstrom’s macroglobulinemia, but polyneuropathy is a common problem.
  • Adding dexamethasone with alternative proteosome inhibibitor ixazomib may be effective.

Study design

  • A multicenter phase 1/2 trial of 60 patients with relapsed Waldenstrom’s macroglobulinemia, treated with ixazomib, rituximab, and dexamethasone (IRD). 
  • Patients received 4 mg oral ixazomib citrate and 20 mg dexamethasone every week on a 28-day cycle. 
  • Rituximab was added in cycle 3.
  • Phase 2 primary endpoint: overall response rate after 8 induction cycles.
  • Funding: Takeda Oncology; Roche; and the Dutch Cancer Society.

Key results

  • Phase 1: ixazomib 4 mg was feasible and continued as phase 2 dose.
  • Phase 2: 50 patients were included.
  • 39 patients completed 8 cycles of induction therapy.
  • 11 patients discontinued treatment due to progression (n=5), toxicity (n=3), intercurrent death (n=2), or insufficient clinical benefit (n=1).
  • 74% of patients achieved the primary endpoint (≥very good partial response [VGPR], 16%; ≥partial response [PR], 52%; at least minimal response [MR], 74%).
  • Best overall response rate was 88% (complete response, 2%; VGPR, 22%; PR, 44%; MR, 20%). 
  • Median follow-up was 19.5 (range, 7-49) months.
  • Median duration of response and median PFS were not reached. 
  • IgM levels decreased significantly from 3.93 to 2.37 g/dL by cycle 2 (P<.001>
  • 15 patients experienced a total of 21 serious adverse events.
  • 6 patients died due to:
    • progressive disease, 2;
    • progressive multifocal leukoencephalopathy, 1 (symptoms present already at entry);
    • unrelated deaths in elderly patients with multiple preexisting comorbidities, 2; and
    • graft vs host disease after progression and subsequent allogeneic stem cell transplantation, 1.